stocktools
Dilution profile // every instrument, one screen, from SEC filings

Quoin Pharmaceuticals, Ltd. (QNRX)

CIK 1671502 · all EDGAR filings →

Overall dilution risk
HIGHworst of 3 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
not every sub-rating was computable; treat as a floor
Offering ability
HIGH$98.2M registered
= total registered offering amount from the fee exhibits of live registrations (bands: $1M / $20M)
one or more live registrations had no structured fee data, so the true total is AT LEAST this
Overhead supply
LOWwarrants = 1% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
NOT COMPUTEDunder 3 years of share history on file
= share count now vs 3 years ago
Cash need
MEDIUM~9.6 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2017-12-312026-08-12

Latest: 70.3M shares as of Aug 12, 2026 (10-Q). Share count fell from 3.35B to 70.3M between Dec 31, 2021 and Aug 12, 2026, a pattern consistent with a reverse split (roughly 1-for-48); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

Warrants outstanding: 399,999 underlying shares, as reported Jul 14, 2022 (6-K).

Reported exercise price: $16.13 (aggregate figure as tagged; individual tranches vary).

Balance-sheet fair value of warrants: $373,599 as of Dec 31, 2021.

Rough fully diluted estimate: 70.7M = 70.3M O/S + 399,999 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 14, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding70.3MAug 12, 2026
+ Warrants (aggregate, as tagged) (if exercised)399,999Jul 14, 2022
Fully diluted estimate70.7M+0.6% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

Registered offering capacity on live registrations: $98.2Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted

S-3Nov 7, 2025$98.2M registeredfiling →
S-1Dec 11, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-1Feb 12, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 1 executed · 1 registered.

UPDATEJun 2, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →
UPDATEDec 5, 2025Prospectus update — often a resale registration, not necessarily new capital424B3 →
EFFECTIVEDec 4, 2025SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDNov 7, 2025S-3 registration — capacity to sell shares, not a sale yetS-3 →
EXECUTEDOct 15, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →
EFFECTIVEApr 3, 2025SEC declared a registration effective — selling can beginEFFECT →
EXECUTEDDec 23, 2024Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →
EFFECTIVEDec 20, 2024SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDDec 18, 2024S-1/A registration — capacity to sell shares, not a sale yetS-1/A →
UPDATEDec 11, 2024Prospectus update — often a resale registration, not necessarily new capital424B3 →
REGISTEREDDec 11, 2024S-1 registration — capacity to sell shares, not a sale yetS-1 →
UPDATENov 8, 2024Prospectus update — often a resale registration, not necessarily new capital424B3 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full QNRX workspace